Lisa Maree Williams/Getty Images News
AstraZeneca (NASDAQ:AZN) announced Tuesday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its anti-PD-L1 immunotherapy Imfinzi as part of a combination regimen for a type of bladder cancer.
Issuing a positive opinion, EMA’s Committee